170 related articles for article (PubMed ID: 16817957)
1. An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients.
Samama MM; Kleber FX
Thromb J; 2006 Jul; 4():8. PubMed ID: 16817957
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients.
Haas S
Semin Thromb Hemost; 1999; 25 Suppl 3():101-5. PubMed ID: 10549724
[TBL] [Abstract][Full Text] [Related]
3. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
Harrington DW
Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
[TBL] [Abstract][Full Text] [Related]
4. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
Turpie AG; Norris TM
Thromb Haemost; 2004 Jul; 92(1):3-12. PubMed ID: 15213839
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.
Miano TA; Cuker A; Christie JD; Martin N; Smith B; Makley AT; Guo W; Hennessy S
Chest; 2018 Jan; 153(1):133-142. PubMed ID: 28823757
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
Siddiqui MA; Wagstaff AJ
Drugs; 2005; 65(7):1025-36. PubMed ID: 15892594
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients.
McGarry LJ; Stokes ME; Thompson D
Thromb J; 2006 Sep; 4():17. PubMed ID: 17005045
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism in the medically ill patient: a call to action.
Bergmann JF; Kher A
Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Dunn CJ; Jarvis B
Drugs; 2000 Jul; 60(1):203-37. PubMed ID: 10929935
[TBL] [Abstract][Full Text] [Related]
14. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
[TBL] [Abstract][Full Text] [Related]
15. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients.
Spyropoulos AC
Chest; 2005 Aug; 128(2):958-69. PubMed ID: 16100192
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.
Wilbur K; Lynd LD; Sadatsafavi M
Clin Appl Thromb Hemost; 2011 Oct; 17(5):454-65. PubMed ID: 20699258
[TBL] [Abstract][Full Text] [Related]
17. Adherence to pharmacological thromboprophylaxis orders in hospitalized patients.
Fanikos J; Stevens LA; Labreche M; Piazza G; Catapane E; Novack L; Goldhaber SZ
Am J Med; 2010 Jun; 123(6):536-41. PubMed ID: 20569760
[TBL] [Abstract][Full Text] [Related]
18. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
19. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
Bergmann JF; Neuhart E
Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
